{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:27:43Z","timestamp":1765700863886},"reference-count":25,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ejca.2008.07.042","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T19:50:20Z","timestamp":1221249020000},"page":"2350-2356","source":"Crossref","is-referenced-by-count":41,"title":["The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?"],"prefix":"10.1016","volume":"44","author":[{"given":"Ferry ALM","family":"Eskens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2008.07.042_bib1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.07.042_bib2","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantano","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2008.07.042_bib6","article-title":"Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)\/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II\/III colon cancer","volume":"26","author":"Allegra","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"New Engl J Med"},{"issue":"suppl","key":"10.1016\/j.ejca.2008.07.042_bib8","article-title":"Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-na\u00efve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704","volume":"25","author":"Manegold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2007.13.1144","article-title":"Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599","volume":"26","author":"Ramalingam","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib10","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"New Engl J Med"},{"issue":"suppl","key":"10.1016\/j.ejca.2008.07.042_bib11","article-title":"Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO","volume":"26","author":"Miles","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl. 1","key":"10.1016\/j.ejca.2008.07.042_bib12","first-page":"S28","article-title":"Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer","volume":"100","author":"Pegram","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2008.07.042_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ejca.2008.07.042_bib14","article-title":"A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer","volume":"26","author":"Forero-Torres","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.07.042_bib16","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.ejca.2008.07.042_bib17","article-title":"CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New Engl J Med"},{"issue":"suppl","key":"10.1016\/j.ejca.2008.07.042_bib19","article-title":"Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)","volume":"26","author":"Figlin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib20","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib21","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejca.2008.07.042_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the california, chicago, and princess margaret hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.07.042_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200868040-00009","article-title":"Bevacizumab: a review of its use in metastatic colorectal cancer","volume":"68","author":"McCormack","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2008.07.042_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11120","article-title":"Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer","volume":"11","author":"Tappenden","year":"2007","journal-title":"Health Technol Assess"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908006096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908006096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T19:28:01Z","timestamp":1545766081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804908006096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":25,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0959804908006096"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2008.07.042","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}